Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study

Authors :: Lumry, William R.
Martinez-Saguer, Inmaculada
Yang, William H.
Bernstein, Jonathan A.
Jacobs, Joshua
Moldovan, Dumitru
Riedl, Marc A.
Johnston, Douglas T.
Li, H. Henry
Tang, Yongqiang
Schranz, Jennifer
Lu, Peng
Vardi, Moshe
Farkas, Henriette
Keith, P.
Yang, W.
Maurer, M.
Martinez-Saguer, I.
Farkas, H.
Reshef, A.
Kivity, S.
Moldovan, D.
Caballero, T.
Guilarte, M.
Hernandez, M.D.
González-Quevedo, M.T.
Banerji, A.
Bernstein, J.
Bewtra, A.
Craig, T.
Fineman, S.
Gower, R.
Jacobs, J.
Johnston, D.
Kashkin, J.
Li, H.H.
Lumry, W.R.
Manning, M.
McNeil, D.
Melamed, I.
Mumneh, N.
Nickel, T.
Panuto, J.
Soteres, D.
Tachdjian, R.
Offenberger, J.
Wedner, J.
Source :: The Journal of Allergy and Clinical Immunology: In Practice; May-June 2019, Vol. 7 Issue: 5 p1610-1618.e4
Publication Year :: 2019
Abstract: Hereditary angioedema (HAE) with C1 inhibitor deficiency (C1-INH) is characterized by swelling of subcutaneous and/or submucosal tissues.

Full Text Access

Tools